Spanish group Insud Pharma has entered into an agreement to sell 55% of its biotech business, mAbxience, to Fresenius Kabi. Founded in 2010, mAbxience has over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals. The company operates three state-of-the-art and R&D manufacturing facilities, located in Spain and Argentina, and has been developing a range of biopharmaceutical products focused on multiple therapeutic areas. mAbxience also operate...